• Vaccine Name: Melanoma DNA vaccine TA2M™ encoding tyrosinase peptides
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0004431
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Human
• Tyrosinase gene engineering:
  • Type: DNA vaccine construction
  • Description: This DNA vaccine expressed two peptides, tyrosinase 207–216 and tyrosinase 1–17, both of which are derived from human tyrosinase (Tagawa et al., 2003).
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0005017
• Immunization Route: Intramuscular injection (i.m.)

Human Response

• Vaccine Immune Response Type: VO_0000286
• Efficacy: The fact that, at a median follow-up of 1 year, 16 of 26 patients still were alive is notable, because the median survival of patients with Stage IV melanoma in recent trials was 7–9 months from first treatment. The 11 patients who had detectable immune responses to tyrosinase 207–216 had appreciably fewer deaths and superior survival compared with the 13 patients who had no immune responses (Tagawa et al., 2003).